With regard to Health Canada's decisions taken with respect to Mifegymiso: (a) is Health Canada capturing data on the safety and efficacy of Mifegymiso on Canadian patients; (b) if the answer to (a) is affirmative, (i) how is the data being obtained, (ii) what data is being obtained, (iii) will the data be made public; (c) will Health Canada conduct a Canadian post-market study independent of the drug manufacturer Linepharma on the safety of Mifegymiso; (d) if the answer to (c) is affirmative, (i) on what date will the study commence, (ii) on what date will the study end, (iii) what methodology will be used, (iv) where will the study be conducted; (e) will Health Canada ensure that the drug manufacturer Linepharma conducts a Phase IV Observational Study on the safety of Mifegymiso on Canadian women; and (f) if the answer (e) is affirmative, (i) on what date will the study commence, (ii) on what date will the study end, (iii) what methodology will be used, (iv) where will the study be conducted?
In the House of Commons on May 3rd, 2018. See this statement in context.